The Unforeseen Path to the Superior Vena Cava

Am J Respir Crit Care Med. 2021 Aug 1;204(3):e51-e53. doi: 10.1164/rccm.202011-4106IM.

Authors

Jacques Boutros¹, Jonathan Benzaquen¹, Charles-Hugo Marquette^{1

2}, Sylvie Leroy^{1

3}

Affiliations

¹ FHU OncoAge, Department of Pulmonary Medicine, CHU de Nice.
² Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, and.
³ Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 7275, Université Côte d'Azur, Nice, France.

PMID: 34166167
DOI: 10.1164/rccm.202011-4106IM

No abstract available

Publication types

Case Reports
Video-Audio Media

MeSH terms

Adenocarcinoma of Lung / complications
Adenocarcinoma of Lung / diagnostic imaging
Adenocarcinoma of Lung / therapy*
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bronchial Fistula / diagnostic imaging*
Bronchial Fistula / etiology
Bronchoscopy
Carboplatin / administration & dosage
Chemoradiotherapy
Humans
Lung Neoplasms / complications
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / therapy*
Pemetrexed / administration & dosage
Response Evaluation Criteria in Solid Tumors
Stents*
Superior Vena Cava Syndrome / diagnostic imaging
Superior Vena Cava Syndrome / etiology
Superior Vena Cava Syndrome / surgery*
Vascular Fistula / diagnostic imaging*
Vascular Fistula / etiology

Substances

Antibodies, Monoclonal, Humanized
Pemetrexed
Carboplatin
pembrolizumab